Table 3.
Frequencies of CYP2D6 and CYP3A gene variants in the investigated TAM-treated breast cancer patients (n = 40)
| Gene | Premenopausal (n = 20) | Postmenopausal (n = 20) | |
|---|---|---|---|
| CYP2D6 | |||
| Activity score | Function | Frequencies of gene variants | |
| 0 | PM | 0 | 0 |
| 0.5 | IM | 0.15 | 0 |
| 1 | Slow NM | 0.30 | 0.2 |
| 1.5 | NM | 0.25 | 0.35 |
| 2 | NM | 0.25 | 0.35 |
| > 2 | UM | 0 | 0 |
| others | 0.05 | 0.10 | |
| CYP3A5 | |||
| *3 | Variant | ||
| AA (*3/*3) | 0.65 | 0.7 | |
| AG (*3/*1) | 0.35 | 0.2 | |
| GG (*1/*1) | 0 | 0.1 | |
| CYP3A4 | |||
| *1b | Variant | ||
| AA (*1/*1) | 0.8 | 0.7 | |
| AG (*1/*1b) | 0.2 | 0.3 | |
| GG (*1b/*1b) | 0 | 0 | |
| *22 | Variant | ||
| CC (*1/*1) | 0.9 | 0.95 | |
| CT (*1/*22) | 0.1 | 0.05 | |
| TT (*22/*22) | 0 | 0 | |